Study details
Enrolling now
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
NCT IDNCT07197554ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
171
Study length
about 4.1 years
Ages
16+
Locations
6 sites in CA, MA, NY +1
What this study is about
Researchers are testing the safety and how well ST-01156 works in people with advanced solid cancers. The trial will be done in two parts. Part 1 (Dose Escalation) will assess the safety, tolerability, pharmacokinetics (PK), and preliminary anticancer activity of SD-01156 in participants with advanced solid malignancies.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ST-01156
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Oncology